Spectrum Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Spectrum Pharmaceuticals's earnings have been declining at an average annual rate of -0.5%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been declining at an average rate of 69.6% per year.
Key information
-0.5%
Earnings growth rate
10.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -69.6% |
Return on equity | -252.6% |
Net Margin | -263.2% |
Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts
May 14Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates
May 12Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC
Sep 20Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?
Sep 16Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection
Sep 09Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'
Aug 21Spectrum Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Jun 04Spectrum Pharmaceuticals: Some Last Words
Feb 25Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Oct 05Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity
Aug 12Spectrum's Big Approval: Any Day Now
Jul 29FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS
Jun 01Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
May 31We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate
Feb 12Spectrum Pharma drops after announcing less-than-favorable Phase 2 data
Dec 22Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like
Dec 21Spectrum Pharma Is Down But Not Out
Nov 16Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib
Nov 11Revenue & Expenses BreakdownBeta
How Spectrum Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 23 | 26 | -68 | 43 | 43 |
31 Dec 22 | 10 | -78 | 39 | 42 |
30 Sep 22 | 0 | -106 | 42 | 51 |
30 Jun 22 | 0 | -117 | 45 | 59 |
31 Mar 22 | 0 | -138 | 56 | 72 |
31 Dec 21 | 0 | -158 | 60 | 87 |
30 Sep 21 | 0 | -169 | 57 | 88 |
30 Jun 21 | 0 | -184 | 60 | 92 |
31 Mar 21 | 0 | -166 | 60 | 85 |
31 Dec 20 | 0 | -171 | 60 | 81 |
30 Sep 20 | 0 | -162 | 60 | 85 |
30 Jun 20 | 0 | -140 | 58 | 78 |
31 Mar 20 | 0 | -136 | 60 | 74 |
31 Dec 19 | 0 | -135 | 60 | 79 |
30 Sep 19 | 0 | -148 | 61 | 86 |
30 Jun 19 | 0 | -191 | 61 | 84 |
31 Mar 19 | 0 | -147 | 60 | 83 |
31 Dec 18 | 0 | -127 | 63 | 75 |
30 Sep 18 | 29 | -102 | 68 | 67 |
30 Jun 18 | 65 | -51 | 74 | 66 |
31 Mar 18 | 99 | -87 | 75 | 64 |
31 Dec 17 | 0 | -101 | 65 | 52 |
30 Sep 17 | 135 | -81 | 72 | 63 |
30 Jun 17 | 132 | -81 | 73 | 59 |
31 Mar 17 | 132 | -84 | 83 | 58 |
31 Dec 16 | 146 | -70 | 86 | 59 |
30 Sep 16 | 162 | -55 | 92 | 56 |
30 Jun 16 | 157 | -56 | 92 | 55 |
31 Mar 16 | 168 | -35 | 87 | 50 |
31 Dec 15 | 163 | -53 | 88 | 51 |
30 Sep 15 | 164 | -50 | 90 | 50 |
30 Jun 15 | 183 | -42 | 94 | 54 |
31 Mar 15 | 185 | -44 | 97 | 74 |
31 Dec 14 | 187 | -46 | 97 | 70 |
30 Sep 14 | 176 | -82 | 98 | 66 |
30 Jun 14 | 171 | -78 | 99 | 65 |
31 Mar 14 | 157 | -84 | 95 | 46 |
31 Dec 13 | 156 | -62 | 94 | 47 |
30 Sep 13 | 184 | -15 | 86 | 50 |
30 Jun 13 | 211 | 14 | 84 | 46 |
31 Mar 13 | 247 | 42 | 86 | 45 |
31 Dec 12 | 268 | 94 | 83 | 42 |
30 Sep 12 | 251 | 95 | 90 | 34 |
Quality Earnings: SPPI is currently unprofitable.
Growing Profit Margin: SPPI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPPI is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.
Accelerating Growth: Unable to compare SPPI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPPI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: SPPI has a negative Return on Equity (-252.59%), as it is currently unprofitable.